肝细胞癌：发病机制、检测和治疗的最新研究。
Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment.
机构信息
Department of Clinical and Biological Sciences, University of Turin, 10125 Turin, Italy.
Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
出版信息
Int J Mol Sci. 2023 Jul 31;24(15):12224. doi: 10.3390/ijms241512224.
Abstract
The most common form of primary liver malignancy is hepatocellular carcinoma (HCC) [...].
摘要
最常见的原发性肝恶性肿瘤是肝细胞癌（HCC）[...]。
相似文献
1
Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment.肝细胞癌：发病机制、检测和治疗的最新研究。
Int J Mol Sci. 2023 Jul 31;24(15):12224. doi: 10.3390/ijms241512224.
2
EASL HCC summit: liver cancer management.EASL HCC 峰会：肝癌管理。
Future Oncol. 2014 May;10(7):1129-32. doi: 10.2217/fon.14.68.
3
Hepatocellular carcinoma in the era of immunotherapy.免疫治疗时代的肝细胞癌
Curr Probl Cancer. 2018 Jan-Feb;42(1):40-48. doi: 10.1016/j.currproblcancer.2017.10.007. Epub 2017 Nov 15.
4
Hepatocellular Carcinoma: New Developments.肝细胞癌：新进展。
Clin Liver Dis. 2023 Feb;27(1):85-102. doi: 10.1016/j.cld.2022.08.004. Epub 2022 Oct 18.
5
[Diagnostic imaging and therapy of hepatocellular carcinoma].[肝细胞癌的诊断成像与治疗]
Dtsch Med Wochenschr. 1997 Dec 12;122(50):1573-5.
6
The effectiveness of selective internal radiation therapy in challenging cases of liver-predominant unresectable hepatocellular carcinoma.选择性内放射治疗在以肝脏为主的不可切除肝细胞癌疑难病例中的疗效。
Future Oncol. 2014 Nov;10(15 Suppl):17-27. doi: 10.2217/fon.14.218.
7
[Diagnosis and treatment of multicentric occurrence of hepatocellular carcinoma].[肝细胞癌多中心发生的诊断与治疗]
Zhonghua Gan Zang Bing Za Zhi. 2004 Mar;12(3):187-9.
8
Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.肝细胞癌：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2008 May;19 Suppl 2:ii27-8. doi: 10.1093/annonc/mdn114.
9
[Fibrolamellar hepatocellular carcinoma].[纤维板层型肝细胞癌]
Harefuah. 2001 Oct;140(10):952-4.
10
Hepatocellular Carcinoma.肝细胞癌。
Crit Care Nurs Clin North Am. 2022 Sep;34(3):289-301. doi: 10.1016/j.cnc.2022.04.004. Epub 2022 Jul 20.
引用本文的文献
1
Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Hepatocellular Carcinoma: A Review of Emerging Applications for Locoregional Therapy.肝细胞癌的定量动态对比增强磁共振成像（DCE-MRI）：局部区域治疗新兴应用综述
Bioengineering (Basel). 2025 Aug 12;12(8):870. doi: 10.3390/bioengineering12080870.
2
Assessing the Predictive Value of NLR and PLRs in Advanced Hepatocellular Carcinoma Patients Receiving First-line Systemic Therapy: Observations from a Tertiary Care Hospital in Pakistan.评估中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLRs）在接受一线全身治疗的晚期肝细胞癌患者中的预测价值：来自巴基斯坦一家三级护理医院的观察结果。
Euroasian J Hepatogastroenterol. 2025 Jan-Jun;15(1):107-112. doi: 10.5005/jp-journals-10018-1462. Epub 2025 Jun 18.
3
Molecular mechanisms underlying the potential anticancer activity of hexane fraction in HCT116 cancer cells.己烷组分在HCT116癌细胞中潜在抗癌活性的分子机制。
3 Biotech. 2025 Aug;15(8):257. doi: 10.1007/s13205-025-04423-1. Epub 2025 Jul 15.
4
Clonorchis sinensis infection remodels chromatin accessibility in hepatocellular carcinoma.华支睾吸虫感染重塑肝细胞癌中的染色质可及性。
Parasit Vectors. 2025 Jul 10;18(1):276. doi: 10.1186/s13071-025-06909-6.
5
Unraveling the Hippo pathway: YAP/TAZ as central players in cancer metastasis and drug resistance.解析河马通路：YAP/TAZ在癌症转移和耐药性中扮演核心角色。
EXCLI J. 2025 Jun 6;24:612-637. doi: 10.17179/excli2025-8351. eCollection 2025.
6
Efficacy of Lenvatinib Versus Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.仑伐替尼与索拉非尼治疗不可切除肝细胞癌的疗效：一项系统评价和荟萃分析
Asian Pac J Cancer Prev. 2025 Jun 1;26(6):1943-1952. doi: 10.31557/APJCP.2025.26.6.1943.
7
Evaluation of the efficacy of laparoscopic hepatolobectomy for primary liver cancer with early combined enteral and parenteral nutritional support.早期肠内与肠外营养支持联合应用对腹腔镜肝叶切除术治疗原发性肝癌疗效的评估
Discov Oncol. 2025 Jun 12;16(1):1079. doi: 10.1007/s12672-025-02851-2.
8
A reliable prognostic model for hepatocellular carcinoma using neutrophil extracellular traps and immune related genes.一种利用中性粒细胞胞外诱捕网和免疫相关基因构建的肝细胞癌可靠预后模型。
Sci Rep. 2025 Jun 3;15(1):19390. doi: 10.1038/s41598-025-01335-1.
9
Assessment of ghrelin serum level and gene polymorphism as a risk factor in progression of chronic viral hepatitis.评估生长激素释放肽血清水平和基因多态性作为慢性病毒性肝炎进展的危险因素。
Sci Rep. 2025 May 8;15(1):16052. doi: 10.1038/s41598-025-99037-1.
10
Exploring the association between chemotherapy and prognosis among patients less than 50 years old with hepatocellular carcinoma: a retrospective cohort study based on the SEER database.探索年龄小于50岁的肝细胞癌患者化疗与预后之间的关联：一项基于监测、流行病学和最终结果（SEER）数据库的回顾性队列研究
Discov Oncol. 2025 May 7;16(1):682. doi: 10.1007/s12672-025-02490-7.
本文引用的文献
1
Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses.肝癌的代谢重编程：免疫反应的新微环境。
Int J Mol Sci. 2023 Apr 18;24(8):7463. doi: 10.3390/ijms24087463.
2
SPRED2: A Novel Regulator of Epithelial-Mesenchymal Transition and Stemness in Hepatocellular Carcinoma Cells.SPRED2：调控肝癌细胞上皮间质转化和干性的新分子。
Int J Mol Sci. 2023 Mar 5;24(5):4996. doi: 10.3390/ijms24054996.
3
Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.肝类器官作为研究原发性肝癌的体外模型。
Int J Mol Sci. 2023 Feb 25;24(5):4529. doi: 10.3390/ijms24054529.
4
Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma.癌症相关成纤维细胞在肝细胞癌进展和治疗中的新作用。
Int J Mol Sci. 2023 Feb 15;24(4):3941. doi: 10.3390/ijms24043941.
5
and Serve as Prognostic Biomarkers Associated with an Inflamed Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma.并作为与肝癌炎症免疫抑制肿瘤微环境相关的预后生物标志物。
Int J Mol Sci. 2023 Feb 5;24(4):3155. doi: 10.3390/ijms24043155.
6
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.PI3K/AKT/mTOR 信号通路在肝癌代谢中的作用。
Int J Mol Sci. 2023 Jan 31;24(3):2652. doi: 10.3390/ijms24032652.
7
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
8
Constitutively Active Androgen Receptor in Hepatocellular Carcinoma.肝细胞癌中的组成性激活雄激素受体。
Int J Mol Sci. 2022 Nov 9;23(22):13768. doi: 10.3390/ijms232213768.
9
Cytotoxic T Cell Expression of Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) in Viral Hepatitis C-Mediated Hepatocellular Carcinoma.白细胞相关免疫球蛋白样受体-1 在丙型肝炎病毒相关肝细胞癌中细胞毒性 T 细胞的表达。
Int J Mol Sci. 2022 Oct 19;23(20):12541. doi: 10.3390/ijms232012541.
10
Inhibition of eIF6 Activity Reduces Hepatocellular Carcinoma Growth: An In Vivo and In Vitro Study.抑制 eIF6 活性可降低肝癌生长：一项体内和体外研究。
Int J Mol Sci. 2022 Jul 13;23(14):7720. doi: 10.3390/ijms23147720.
Zotero 插件